文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症消化、代谢与肾脏急症

ICU热射病目标温度管理35°C与37°C对比:一项先导性随机对照试验

Targeted Temperature Management at 35°C vs. 37°C for Heatstroke in ICU: A Pilot Randomized Controlled Trial.
PubMed 文献 · Crit Care Med · 2026-08-06
一句话结论在插管热射病患者中,35°C治疗性低温未改善28天神经功能或生存,且严重胃肠损伤和心律失常显著增加,不应常规采用。

这项先导性多中心RCT在中国10个三级ICU纳入35例插管热射病成人,1:1随机接受35°C治疗性低温(2小时内达标并维持48小时)或对照性正常体温(体温>38.0°C时才降温,维持36.5–37.5°C)。招募率83.7%、保留率97.2%、方案依从性>88%,证实大规模试验可行。28天不良功能结局(17.6% vs 16.7%)和生存(82.4% vs 83.3%)无显著差异,但低温组严重胃肠损伤(52.9% vs 0%,p<0.001)和心律失常(41.2% vs 11.1%,p=0.045)显著更高。低温组100%需「冬眠合剂」控制寒战,提示额外安全性顾虑。

要点

  • 插管热射病患者35°C低温 vs 对照性正常体温:28天不良功能结局17.6% vs 16.7%、生存82.4% vs 83.3%,均无显著差异。
  • 低温组严重胃肠损伤(AGI 3–4级)52.9% vs 0%(p<0.001),心律失常41.2% vs 11.1%(p=0.045),安全性信号明确。
  • 低温组100%需「冬眠合剂」(氯丙嗪+异丙嗪+哌替啶)控制寒战,对照性正常体温组仅27.8%(p<0.001)。
  • 该先导试验招募率83.7%、保留率97.2%、方案依从性>88%,支持开展大规模RCT的可行性。
  • 基于当前证据,35°C治疗性低温不应在ICU热射病管理中常规采用。

适用人群与场景

  • 中国10个三级ICU的插管成人(≥18岁)热射病患者,符合预设诊断标准。
  • 排除:非环境性高热、预期24小时内死亡、或存在温度管理禁忌者。

诊断标准与关键阈值

  • 热射病诊断依据原文所述预设诊断标准(原文未列出具体条目)。
  • 低温组目标:2小时内达到35.0°C并维持48小时;对照性正常体温组仅体温>38.0°C时降温,目标核心体温36.5–37.5°C。
  • 寒战按阶梯方案处理,难治性寒战以「冬眠合剂」(氯丙嗪、异丙嗪、哌替啶)作为挽救治疗。

处置流程与药物剂量

  • 第一步:插管热射病患者随机1:1分配至35°C治疗性低温或对照性正常体温策略。
  • 第二步(低温组):采用冰袋、预冷毯和冰盐水静脉输注联合快速降温,2小时内达到35.0°C,维持48小时。
  • 第三步(对照性正常体温组):仅体温>38.0°C时采用常规降温(冰袋、32°C毯),维持核心体温36.5–37.5°C。
  • 第四步:两组均按阶梯方案处理寒战,难治性寒战使用「冬眠合剂」(氯丙嗪、异丙嗪、哌替啶)挽救治疗。

红旗征与不能漏的情况

  • 低温组严重胃肠损伤(AGI 3–4级)发生率达52.9%,显著高于对照组的0%(p<0.001),需警惕。
  • 低温组心律失常发生率41.2%,显著高于对照组的11.1%(p=0.045),需监测。
  • 低温组100%需药物控制寒战,提示寒战管理负担和额外安全性顾虑。

研究设计与关键结果

  • 干预为35°C治疗性低温(2小时内达标、维持48小时)vs 对照性正常体温(>38.0°C才降温、维持36.5–37.5°C)。
  • 招募率83.7%、保留率97.2%、方案依从性>88%。
  • 28天不良功能结局17.6% vs 16.7%,生存82.4% vs 83.3%,均无显著差异。
  • 严重胃肠损伤(AGI 3–4级)52.9% vs 0%(p<0.001);心律失常41.2% vs 11.1%(p=0.045);冬眠合剂使用100% vs 27.8%(p<0.001)。

证据类型、等级与局限

  • 证据类型:先导性多中心随机对照试验(pilot multicenter RCT)。
  • 局限:样本量小(35例)、先导性设计、主要目的为可行性评估,临床结局为初步数据。
  • 原文结论:支持开展大规模RCT的可行性,但低温策略不应常规用于ICU热射病管理。

对床旁实践的改变

  • 不应将35°C治疗性低温作为ICU插管热射病的常规策略。
  • 如实施低温,需警惕严重胃肠损伤(AGI 3–4级)和心律失常风险显著增加。
  • 低温策略下几乎全部患者需药物控制寒战(冬眠合剂),需评估相关安全性负担。
  • 适用人群为插管成人热射病患者;非环境性高热、预期24小时内死亡或温度管理禁忌者不适用。

指南或共识出处

  • Crit Care Med:Targeted Temperature Management at 35°C vs. 37°C for Heatstroke in ICU: A Pilot Randomized Controlled Trial(原文未提供发表年份)。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate the feasibility of conducting a trial comparing targeted temperature management (TTM) at 35°C-37°C in intubated heatstroke patients, while collecting preliminary data on safety and clinical outcomes.

DESIGN: Pilot multicenter randomized clinical trial (June to December 2024).

SETTING: Ten tertiary ICUs in China.

PATIENTS: Thirty-five intubated adults (18 yr or older) with heatstroke meeting predefined diagnostic criteria. Key exclusions: nonenvironmental hyperthermia, expected death within 24 hours, or contraindications to temperature management.

INTERVENTIONS: Patients were randomly assigned 1:1 to two TTM strategies. The therapeutic hypothermia group received protocolized rapid cooling using a combination of ice packs, precooled blankets, and ice-cold IV saline to achieve the target of 35.0°C within 2 hours, which was then maintained for 48 hours. The controlled normothermia group received conventional cooling measures (ice packs, 32°C blankets) only if body temperature exceeded 38.0°C, with the goal of maintaining core temperature between 36.5°C and 37.5°C. Shivering was managed according to a stepwise protocol, with a "lytic cocktail" (chlorpromazine, promethazine, and meperidine) available as rescue therapy for refractory shivering in both groups.

MEASUREMENTS AND MAIN RESULTS: Recruitment rate was 83.7%, retention rate was 97.2%, and protocol adherence exceeded 88%. For clinical outcomes, no significant differences were observed in 28-day poor functional outcome (17.6% vs. 16.7%) or survival (82.4% vs. 83.3%). However, therapeutic hypothermia was associated with significantly higher rates of severe gastrointestinal injury (Acute Gastrointestinal Injury grade 3-4: 52.9% vs. 0%; p < 0.001) and arrhythmias (41.2% vs. 11.1%; p = 0.045). The lytic cocktail was required in 100% of hypothermia-group patients vs. 27.8% in the normothermia group ( p < 0.001).

CONCLUSIONS: This pilot study confirms the operational feasibility of a large-scale randomized clinical trial. However, therapeutic hypothermia was associated with significantly worse gastrointestinal injury and higher arrhythmia incidence, without evidence of neurologic or survival benefit. The universal requirement for pharmacological shivering control in the hypothermia group raises additional safety considerations. Based on current evidence, this strategy should not be routinely adopted in ICU heatstroke management.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Wang YC, Wang JW, Li X, et al. Targeted Temperature Management at 35°C vs. 37°C for Heatstroke in ICU: A Pilot Randomized Controlled Trial. Crit Care Med. 2026. PMID: 42560130. doi:10.1097/CCM.0000000000007266

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。